Recent industry guidance aims to anchor rapid COVID-19 vaccine development in good manufacturing practice protocols. Major bio/pharmaceutical companies and contract service providers leading the charge to bring COVID-19 vaccines to market are familiar with established good manufacturing practices (GMPs). To support manufacturers in the rush to develop a vaccine, FDA, in June 2020, released industry guidance highlighting the development and licensure of COVID-19 vaccines. Click Here For Complete Article Text
|
|||||||||||||||||||||||||||
Application Sequencing | |||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | ||||||||||||||||||
|
|
|
|
|
|
|
|